UPDATE: Baird's Skorney, When Asked If Neurocrine Shares Rebound Is Related To Traders Circulating Data From A Clinicaltrial.gov Study, Says 'I Don't Think So. The Rebound Seems Pretty Nominal And In-line With The Rest Of The Sector.'